Cargando…

Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin

Detalles Bibliográficos
Autores principales:	Matsubayashi, Yasuhiro, Yoshida, Alkihiro, Suganami, Hideki, Oe, Momoko, Sato, Takaaki, Yaguchi, Yuta, Fujihara, Kazuya, Yamada, Takaho, Tanaka, Shiro, Kaku, Kohei, Sone, Hirohito
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2022
Materias:	Research Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825934/ https://www.ncbi.nlm.nih.gov/pubmed/35979908 http://dx.doi.org/10.1111/dom.14836

Ejemplares similares

Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin
por: Matsubayashi, Yasuhiro, et al.
Publicado: (2021)

Association of increased hepatic insulin clearance and change in serum triglycerides or β‐hydroxybutyrate concentration via the sodium/glucose‐cotransporter 2 inhibitor tofogliflozin
por: Matsubayashi, Yasuhiro, et al.
Publicado: (2020)

Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance
por: Nojima, T., et al.
Publicado: (2020)

Sodium–glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline
por: Tobe, Kazuyuki, et al.
Publicado: (2017)

Renal effects of a sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, in relation to sodium intake and glycaemic status
por: Nunoi, Kiyohide, et al.
Publicado: (2019)

Effects of sodium‐glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes
por: Nunoi, Kiyohide, et al.
Publicado: (2018)

Impact of prior cerebrovascular disease and glucose status on incident cerebrovascular disease in Japanese
por: Oe, Momoko, et al.
Publicado: (2021)

Dipeptidyl peptidase‐4 inhibitor, anagliptin, alters hepatic insulin clearance in relation to the glycemic status in Japanese individuals with type 2 diabetes
por: Abe, Takahiro, et al.
Publicado: (2021)

Basal insulin secretion capacity predicts the initial response and maximum levels of beta‐hydroxybutyrate during therapy with the sodium‐glucose co‐transporter‐2 inhibitor tofogliflozin, in relation to weight loss
por: Sato, Yuichi, et al.
Publicado: (2019)

Impact of metabolic syndrome and metabolic dysfunction-associated fatty liver disease on cardiovascular risk by the presence or absence of type 2 diabetes and according to sex
por: Matsubayashi, Yasuhiro, et al.
Publicado: (2022)

Anaemia, Haemoglobin Level and Cause-Specific Mortality in People with and without Diabetes
por: Kengne, Andre Pascal, et al.
Publicado: (2012)

Long‐term safety and efficacy of the sodium–glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon‐like peptide‐1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52‐week open‐label, multicenter, post‐marketing clinical study
por: Terauchi, Yasuo, et al.
Publicado: (2019)

Haemoglobin and anaemia in the SMART study
por: Mocroft, A, et al.
Publicado: (2010)

Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study
por: Kaku, Kohei, et al.
Publicado: (2014)

Splenic Infarctions in Polycythaemia Vera are Not Always a Catastrophe
por: Abdalla, ELMustafa, et al.
Publicado: (2022)

Comparison of Combined Tofogliflozin and Glargine, Tofogliflozin Added to Insulin, and Insulin Dose-Increase Therapy in Uncontrolled Type 2 Diabetes
por: Suzuki, Katsunori, et al.
Publicado: (2016)

Comparison of baseline characteristics and clinical course in Japanese patients with type 2 diabetes among whom different types of oral hypoglycemic agents were chosen by diabetes specialists as initial monotherapy (JDDM 42)
por: Fujihara, Kazuya, et al.
Publicado: (2017)

Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin
por: Ouchi, Motoshi, et al.
Publicado: (2018)

Polycythaemia treated with nephrectomy
por: Thuesen, Anne Daugaard, et al.
Publicado: (2011)

Koilonychia and Polycythæmia Vera
por: Glazebrook, A. J.
Publicado: (1944)

Haemoglobin levels for population from Gambo, a rural area of Ethiopia, and their association with anaemia and malaria
por: Santana-Morales, Maria A, et al.
Publicado: (2013)

Ambient Air Pollution Exposure Association with Anaemia Prevalence and Haemoglobin Levels in Chinese Older Adults
por: Elbarbary, Mona, et al.
Publicado: (2020)

Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice
por: Obara, Koki, et al.
Publicado: (2017)

The sodium–glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice
por: Li, Zi, et al.
Publicado: (2020)

The Effect of Sodium-Dependent Glucose Cotransporter 2 Inhibitor Tofogliflozin on Neurovascular Coupling in the Retina in Type 2 Diabetic Mice
por: Hanaguri, Junya, et al.
Publicado: (2022)

Ability of Current Machine Learning Algorithms to Predict and Detect Hypoglycemia in Patients With Diabetes Mellitus: Meta-analysis
por: Kodama, Satoru, et al.
Publicado: (2021)

Epoetin-β treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events
por: Aapro, M, et al.
Publicado: (2009)

Regarding: ‘Epoetin β treatment in patients with cancer chemotherapy induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events’
por: Schwarzer, G
Publicado: (2009)

Rates and risk factors for amputation in people with diabetes in Japan: a historical cohort study using a nationwide claims database
por: Kaneko, Masanori, et al.
Publicado: (2021)

Anaemia in Lambs and Kids Reared Indoors on Maternal Milk and the Impact of Iron Supplementation on Haemoglobin Levels and Growth Rates
por: Crilly, James Patrick, et al.
Publicado: (2022)

Chronic Cyanosis, with Polycythæmia and Enlarged Spleen
por: Begg, C., et al.
Publicado: (1905)

A Case of Erythræmia or Splenic Polycythæmia
por: Parker, G.
Publicado: (1920)

Foetal Haemoglobin, Erythrocytes Containing Foetal Haemoglobin, and Hematological Features in Congolese Patients with Sickle Cell Anaemia
por: Tshilolo, L., et al.
Publicado: (2012)

Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models
por: Suzuki, M, et al.
Publicado: (2014)

Residual Effect of Sodium Glucose Cotransporter 2 Inhibitor, Tofogliflozin, on Body Weight After Washout in Japanese Men With Type 2 Diabetes
por: Kakuda, Hirokazu, et al.
Publicado: (2019)

Hæmoglobin Levels in Adolescent Schoolchildren
por: Davison, B. C. Clare
Publicado: (1964)

Haemoglobin Levels in Blood Donors
por: Marshall, Alice J.
Publicado: (1946)

Haemoglobin A(1C) Levels Constantly Below Lower Reference Limit in a Diabetic Patient With Microcytic Anaemia
por: Fan, Frank S, et al.
Publicado: (2019)

Benign familial polycythaemia in a young male
por: Somnath, Maitra, et al.
Publicado: (2012)

Unusual Neurological Symptoms in Polycythæmia Rubra Vera
por: Grunberg, A., et al.
Publicado: (1950)

Cannot write session to /tmp/vufind_sessions/sess_vuvsf6tnt12lg38o3uihgmgtbo